Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.
$ARDX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | Neutral → Overweight | Piper Sandler | |
| 9/3/2025 | $14.00 | Strong Buy | Raymond James |
| 6/18/2025 | $10.00 | Buy | H.C. Wainwright |
| 5/2/2025 | $11.00 | Strong Buy → Outperform | Raymond James |
| 3/7/2025 | Buy | Ladenburg Thalmann | |
| 3/4/2025 | $14.00 | Buy | BTIG Research |
| 11/11/2024 | $11.00 → $5.50 | Buy → Neutral | H.C. Wainwright |
| 7/2/2024 | $15.00 → $7.00 | Overweight → Neutral | Piper Sandler |
DAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (NASDAQ:ARDX), a biopharmaceutical company with a vision of creating a healthier tomorrow for patients, today announced a multi-year partnership naming Ardelyx as an official corporate pharmaceutical Marketing Partner of the LPGA Tour. The exclusive partnership unites two organizations dedicated to empowering women to take control of their health. "This partnership represents a natural alignment between Ardelyx's mission and the LPGA's platform to support the digestive health of women, who account for more than 90 percent of those living with conditions lik
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
Piper Sandler upgraded Ardelyx from Neutral to Overweight
Raymond James resumed coverage of Ardelyx with a rating of Strong Buy and set a new price target of $14.00
H.C. Wainwright resumed coverage of Ardelyx with a rating of Buy and set a new price target of $10.00
144 - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs for new IBSRELA indication and next-generation NHE3 inhibitor launched Company is well capitalized to meet current business objectives Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2025. The call will include commentary from members of the Ardelyx Executive Leadership Team including Mike Raab, President and Chief Executive Officer, Sue Hohenleitner, Chief Financial Officer, Eric Foster, Chief Commercial Officer, and Laura
Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH® Q3 revenue of $27.4 million, up 9% compared to Q2 2025 Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic areas Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet signifi
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer Justin Renz, Chief Financial and Operations Officer, to transition out of the Company WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs today announced changes to the Executive Leadership Team. The company announced the appointment of Edward Conner, M.D. to the position of Chief Medical Officer. Dr. Conner is a seasoned biopharmaceutical executive with more than two de
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and Strategy, has been promoted to Chief Business Officer, and James P. Brady has joined the company as Chief Human Resources Officer. Since joining Ardelyx in March 2024, Mr. Kelliher has established himself as important leader driving Ardelyx's long-term growth and value creation strategies. In his newly expanded role as Chief Business Officer, Mr.